Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say

Illumina on Thursday forecast its annual core business revenue to be nearly flat compared to fiscal year 2023 as subdued demand for its genetic testing tools and diagnostics products extends into this year.

Illumina forecasts flat 2024 sales as sluggish demand drags on

Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and Q4 2022 GAAP diluted loss per share of $(7.34) for fiscal year 2023, which included goodwill and intangible impairments of $821 million related to the GRAIL segment, compared to GAAP diluted loss per share of $(28.00) for fiscal year 2022, which included goodwill impairment of $3.91 billion related to the GRAIL segment Non-GAAP diluted earnings per share of $0.86 for fiscal year 2023, compared to non-GAAP diluted earnings per share of $2.12 for fiscal year 2022 For fiscal year 2024, expect Core Illumina revenue that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin of approximately 20% On December 17, 2023, Illumina announced it will divest GRAIL. The GRAIL divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the divestiture terms by the end of the second quarter of this year.

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

Harmony Biosciences Holdings

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

HRMY or ILMN: Which Is the Better Value Stock Right Now?

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Seeking Clues to Illumina (ILMN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

CRISPR Therapeutics

Vertex Pharmaceuticals

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world.

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements

Exact Sciences

Guardant Health Inc

I'm bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to the individual characteristics of each patient.

3 Stocks to Buy for the Age of Personalized Medicine

Despite recent challenges, Illumina rebounds with strong preliminary Q4 results, led by the successful NovaSeq X launch and strategic alliances, positioning itself as a key player in the genomics transformation. Illumina faces hurdles like the Grail acquisition fallout and economic challenges, but with a new CEO's vision, the company focuses on driving genomics forward, emphasizing customer partnerships and product innovation. Illumina's conservative valuation, positive industry trends, and potential recovery make it a Strong Buy.

Illumina: One Of The Most Hated Stocks In Healthcare Is Looking Like A Strong Buy

Quest Diagnostics

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives.

The Top 3 Stocks in the High-Potential ‘Cancer Testing' Market

Asensus Surgical

Editas Medicine

Hologic

Johnson & Johnson

Moderna

Verve Therapeutics

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.

Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results

Ginkgo Bioworks Holdings

The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network  BOSTON and SAN DIEGO , Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally. Concentric is building a global pathogen monitoring network—a "bioradar" system —in countries around the world to detect, characterize, and rapidly respond to biological threats and help drive informed decision-making in support of global health objectives.

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #biotech--Illumina® Ventures Labs, an early-stage company creation and investment engine, is now operational and finalizing agreements with several startups.

Illumina Ventures Labs Launches in the US and the UK to Enable More Rapid Value-Creation for Start-Ups Advancing Human Health

Illumina, Inc. (ILMN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

SAN DIEGO , Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time (12:00pm Eastern Time).

Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023

The beaten-down stock got a couple of analyst upgrades. Illumina also confirmed it would sell Grail, its controversial 2021 acquisition.

Why Illumina Rallied 36.6% in December

NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Illumina investors who were adversely affected by alleged securities fraud between September 21, 2020 and November 9, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc.(ILMN) Investors of a Class Action Lawsuit and Upcoming Deadline

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between September 21, 2020 and November 9, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 10, 2023, after the market closed, Illumina reve.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Illumina, Inc ("Illumina" or the "Company") (NASDAQ: ILMN).   The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv- 02327, is on behalf of persons and entities that purchased or otherwise acquired Illumina securities between August 18, 2021 and October 16, 2023, inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Illumina, Inc. of Class Action Lawsuit and Upcoming Deadline - ILMN

SAN DIEGO , Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence of disease following clinical intervention.

Illumina expands collaboration with Janssen to advance molecular residual disease cancer test

NEW YORK , Jan. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Illumina, Inc.. Shareholders who purchased shares of ILMN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 - (NASDAQ: ILMN)

SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024

If you suffered losses exceeding $100,000 investing in Illumina securities between September 21, 2020 and November 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ILMN.

ILLUMINA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

AGD delivered ~86,000 whole genomes in 2023, including a unique diverse ancestry cohort Expanded pharma engagement enhances AGD's ability to develop multiomic datasets SAN DIEGO , Jan. 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced three new members of the Alliance for Genomic Discovery (AGD). Bristol Myers Squibb (BMS), GSK and Novo Nordisk join founding member organizations AbbVie, Amgen, AstraZeneca, Bayer, and Merck.

News for Illumina Stock (ILMN)